Dizal's Zegfrovy Achieves Phase 3 Success in First-Line NSCLC with EGFR Exon 20 Insertion, Challenging Chemotherapy Standard
Dizal's Zegfrovy Achieves Phase 3 Success in First-Line NSCLC with EGFR Exon 20 Insertion, Challenging Chemotherapy Standard